@article{65fddc0200074767a280410ca23777ce,
title = "Hymenoptera venom immunotherapy: Past, present, and future",
author = "John Oppenheimer and Golden, \{David B.K.\}",
note = "Funding Information: Disclosures: Dr Oppenheimer reported working as a consultant/adviser for AstraZeneca, GlaxoSmithKline, Mylan, Novartis, and Teva; receiving royalties from UpToDate; and receiving research funding from AstraZeneca, Medimmune, Novartis, and Sanofi. Dr Golden reported serving on the speaker bureau (honoraria) and clinical trials for Genentech and Stallergenes/Greer. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2018",
month = sep,
doi = "10.1016/j.anai.2018.06.006",
language = "English (US)",
volume = "121",
pages = "276--277",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "3",
}